Abstract:e24141 Background: Current treatments for SCLC produce transient responses – 2-year survival is 5%. One reason is that the treatments apply stress upstream of p53 to upregulate it (cytotoxicity), but p53 is genetically inactivated in SCLC, enabling ready selection for resistant cells. We are hence developing towards clinical trials new modalities to cytoreduce SCLC by non-cytotoxic, p53-independent mechanisms. Methods: A murine p53-null SCLC cell line (F1339), developed by tracheal infection of Rblox/p53lox mice with Adeno-CMV-Cre, was inoculated into B6/129 mice by tail vein. After documenting engraftment, mice were treated with PBS, etoposide 8 mg/kg 3X/wk + cisplatin 12 mg/kg 1X/wk, THU-Dec/5Aza (10/0.1/1 mg/kg 3X/wk) or anti-PD1 (5 mg/kg q5d) (n = 5/group). Tumor burden, overall survival (OS), drug pharmacodynamics and metabolism, myeloid derived suppressor cells (MDSCs), and T-cells were measured. Results: The SCLC cells were resistant to clinical concentrations of etoposide/cisplatin (ECis), but were sensitive to DNA methyltransferase 1 (DNMT1)-depletion by non-cytotoxic concentrations of the DNMT1-depleting pyrimidine analogue clinical drugs decitabine (Dec 0.5 µM) or 5-azacytidine (5Aza 5 µM). However, the pyrimidine metabolism network in the cells reacted to Dec and 5Aza challenge with shifts in DCK, UCK2 and CDA expression that reflexively dampened drug uptake, causing resistance after 4 weeks in vitro. To outmaneuver these metabolic reflexes, Dec and 5Aza were alternated, and tetrahydrouridine (THU) to inhibit CDA was added. In vivo, THU-Dec/5Aza significantly extended OS ~2-fold (Log rank p < 0.01); decreased tumor burden (PBS 3.53 g, ECis 3.45 g, THU-Dec/5Aza 1.09 g); increased lymphocyte counts (CD4: PBS 0.99, THU-Dec/5Aza 1.81 k/µL, p < 0.01; CD8: PBS 0.8, THU-Dec/5Aza 1.66 k/µL, p < 0.01); and decreased MDSCs (G-MDSC: PBS 0.13, THU-Dec/5Aza 0.03 k/µL, p < 0.01; M-MDSC: PBS 0.28, THU-Dec/5Aza 0.08 k/µL, p < 0.01). Anti-PD1 alone, like ECis, provided minimal benefit in the syngeneic model of SCLC. Conclusions: Pyrimidine metabolism reflexes to Dec/5Aza challenge can be rationally outmaneuvered, for meaningful non-cytotoxic DNMT1-depleting therapy of ECis/anti-PD1-resistant SCLC.

Synthesis and biological evaluation of novel penindolone derivatives as potential antiproliferative agents against SCLC in vitro

Design, Synthesis and Biological Evaluation of Novel 2,3-Indolinedione Derivatives Against Mantle Cell Lymphoma.

Synthesis and biological assessment of indole derivatives containing penta-heterocycles scaffold as novel anticancer agents towards A549 and K562 cells

Design, Synthesis and Biological Evaluation of Novel Nitric Oxide-Donating Podophyllotoxin Derivatives As Potential Antiproliferative Agents Against Multi-Drug Resistant Leukemia Cells

Synthesis, biological evaluation and mechanism study of a class of benzylideneindanone derivatives as novel anticancer agents

Synthesis, biological evaluation and mechanism study of chalcone analogues as novel anti-cancer agents

Synthesis and biological evaluation of Schizandrin derivatives as potential anti-cancer agents

Design, Synthesis, and Biological Evaluation of Novel Apigenin Derivatives as Potential Antitumor Agents

Synthesis and Biological Evaluation of 3-((1-Methyl-1H-pyrrol-2-yl)methylene)indolin-2-one Derivatives as Potent Anticancer Active Agents

Design, synthesis and anti-NSCLC activity of hybrids of anilinopyrimidines and diazeniumdiolates

The Synthesis and Biological Evaluation of Sanguinarine Derivatives As Anti-Non-small Cell Lung Cancer Agents

Synthesis And Biological Evaluation Of Novel Indoline-2,3-Dione Derivatives As Antitumor Agents

Synthesis and biological evaluation of novel Jiyuan Oridonin A-1,2,3-triazole-azole derivatives as antiproliferative agents.

Synthesis and Evaluation of Novel 5-Sulfonyl-indolin-2-ones As Potent Cytotoxic Agents

Synthesis and in vitro antitumor activity evaluation of novel 5-cyano-6-phenyl-2,4-disubstituted-pyrimidine derivatives

Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo

Design, Synthesis and Biological Evaluation of Biphenyl-1,2,3-Triazole Hybrid Analogues as PD-1/PD-L1 Inhibitors

Novel 1,3,4-Trisubstituted Pyrazolopyrimidine Derivatives Show Potent Antiproliferative Activity in Mantle Cell Lymphoma

In Vivo Validation of Novel P53-Independent Therapeutic Modalities for Small Cell Lung Cancer (SCLC).

A Novel Myricetin Derivative with Anti-cancer Properties Induces Cell Cycle Arrest and Apoptosis in A549 Cells.

Synthesis, SAR Study and Biological Evaluation of Novel Pyrazolo[1,5-A]pyrimidin-7-yl Phenyl Amides As Anti-Proliferative Agents